RxDoctor Payments DataLook up a doctor →

Zahra Pakbaz, MD

Hematology · Orange, CANPI 1942463377

Payments from drug & device makers

$1,639,560in general payments, 2019–2025

Across 227 payments — averaging $7222.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$815K
  • Global Blood Therapeutics, Inc.$353K
  • Amgen$197K
  • Vertex$48K
  • Novo Nordisk AS$43K
  • CSL Behring$41K
  • plus $143K from 10 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis41$814,885
Global Blood Therapeutics, Inc.73$352,872
Amgen9$197,234
Vertex11$48,380
Novo Nordisk AS7$42,896
CSL Behring8$40,572
Pfizer4$32,088
Agios Pharmaceuticals, Inc.17$28,798
AstraZeneca21$28,411
Sanofi16$17,156
Dova Pharmaceuticals8$15,065
Sobi, Inc6$14,122
Terumo BCT, Inc.2$6,300
Bristol Myers Squibb1$500
Novo Nordisk2$250
AbbVie1$31

How this compares

$1,639,560 in reported general payments places this provider in the 70th percentile of 178 hematology providers in California.

See all hematology providers in California

Medicare billing

Part B allowed, 2024
$67,553
Medicare patients
166
Services billed
725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →